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Abstract
Cisplatin, carboplatin, and oxaliplatin anticancer drugs are commonly used to treat lung, colorectal,
ovarian, breast, head/neck, and genitourinary cancers. However, the efficacy of platinum-based drugs
is often compromised because of the substantial risk for severe toxicities, including neurotoxicity.
Neurotoxicity can result in both acute and chronic debilitation. Moreover, colorectal cancer patients
treated with oxaliplatin more often discontinue therapy due to peripheral neuropathy than for tumor
progression, potentially compromising patient benefit. Numerous methods to prevent neurotoxicity
have so far proven unsuccessful. In order to circumvent this life-altering side effect, while taking
advantage of the antitumor activities of the platinum agents, efforts to identify mechanism-based
biomarkers are underway. In this review, we detail findings from the current literature for genetic
markers associated with neurotoxicity induced by single agent and combination platinum
chemotherapy. These data have the potential for broad clinical implications if mechanistic
associations lead to the development of toxicity modulators to minimize the noxious sequelae of
platinum chemotherapy.
The chemotherapy drugs cisplatin, carboplatin, and oxaliplatin are commonly used for the
treatment of lung, colorectal, ovarian, breast, head/neck, bladder and testicular cancers (Fig.
1). Cisplatin was approved for the treatment of both ovarian and testicular cancer in 1978 (1)
and is also administered for many other types of solid tumors. Subsequently, carboplatin was
approved in March, 1989 for treatment of ovarian cancer. In 2002, a third-generation platinum
drug, oxaliplatin, was approved for treatment of metastatic colorectal cancer (2). Cisplatin is
the most commonly used chemotherapy drug in the USA (3). Unfortunately, the benefit of
these frequently prescribed drugs is compromised by severe side effects including
neurotoxicity.
Recent meta-analyses have compared platinum and non-platinum treatments for various cancer
types. A meta-analysis on individual patient data concluded that cisplatin was superior to
carboplatin for non-small cell lung cancer (NSCLC) in terms of response rate and prolonged
survival without an increase in severe side effects (4). By analyzing over 1700 ovarian cancer
patients from six randomized trials, another meta-analysis determined that the inclusion of
cisplatin in front-line therapy of stage III ovarian cancers improves survival (5). Platinum-
based regimens had been shown to have a slightly higher 1-year survival rate than non-
platinum-based regimens in metastatic non-small lung cancer patients (p=0.03). Analysis of
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17 trials that included 4920 NSCLC patients indicated that the platinum-based treatments are
associated with a higher risk of anemia, nausea, and neurotoxicity (p=0.02) (6). Clearly, the
use of platinum drugs is essential in the fight against cancer, however the toxic side effects
must be attenuated in order to reap the maximum benefits.
The second generation platinum drug carboplatin is a more stable analogue but has equivalent
activity, in come cancer types, to cisplatin. Carboplatin is part of first-line therapy for ovarian
cancer, typically in combination with a taxane. Lung cancer is also treated with carboplatin,
in combination therapy with vinorelbine, bevacizumab, etopside, gemcitabine, or paclitaxel
(among others) (7). The negative side effects of carboplatin combinations vary with the
partnering agent. For example, vinorelbine/carboplatin treatment has less incidence of grade
3–4 toxicities, than gemcitabine/carboplatin (8). The efficacy of single agent therapy for
NSCLC is generally improved by the addition of carboplatin (9).
Oxaliplatin, the third-generation platinum drug, is the standard of treatment in conjunction with
5-fluorouracil/ leucovorin (5-FU/LV) for locally advanced and metastatic cancer of the colon
or rectum. It has shown improved survival in the adjuvant setting among Stage III patients
compared to 5-FU/ LV treatment as well as in first-line treatment of metastatic disease,
compared with 5-FU/irinotecan therapy (10). Importantly, the incidence of neurotoxicity is
increased with the addition of oxaliplatin (11). The FDA noted that over 70% of the patients
receiving oxaliplatin are affected by some degree of sensory neuropathy (12). Most
importantly, neurotoxicity, and not tumor progression, is often the cause of treatment
discontinuation. An additional recent study examining 383 patients treated with oxaliplatin and
irinotecan showed that 52% of patients required dose reduction due to adverse events, including
neurotoxicity, and that 26% required hospitalization because of these negative events (13).
Platinum Toxicity
The general toxicity profile differs between the three platinum drugs. Cisplatin may cause
severe renal tubular damage and reduces glomerular filtration. Optimal administration requires
concurrent saline hydration and mannitol diuresis to minimize the likelihood of potentially
lethal damage to the kidneys (14). Cisplatin causes the most severe nausea and vomiting of the
approved platinum compounds which can usually be prevented or managed with current
antiemetic regimens. Peripheral neurotoxicity is the most common dose-limiting problem
associated with modern cisplatin therapy. Cisplatin neurotoxicity is first characterized by
painful paresthesias and numbness which typically occurs during the first few drug cycles.
Loss of vibration sense, paraesthesia and ataxia can become apparent after several treatment
cycles. Additionally, 75–100% of patients treated with cisplatin show some level of ototoxicity.
Ototoxicity caused by cisplatin is cumulative and can be irreversible, therefore monitoring by
audiograms should be considered. Cisplatin also causes mild hematological toxicity.
The dose-limiting toxicity of carboplatin is thrombocytopenia, which is dose-dependent and
varies in severity based on the individual. Because the toxicities are dose-dependent, alternative
methods of ensure appropriate dose are in practice. By measuring glomerular filtration rate
(GFR), Barrett et al were able to take into account the body mass index of all patients
individually (15). They determined that there was no association between body mass index and
prognosis in ovarian cancer patients. However, Ekhart and colleagues established the
importance of the Calvert formula (based on GFR) for dose determination with targeted
carboplatin exposures (16). Alternatively, a patient with normal renal function should be given
a flat dose based on the mean population carboplatin clearance(16). Patients treated with
carboplatin are also at a higher risk of anemia than those treated with cisplatin (p=0.02) (6).
The neurotoxicity resulting from carboplatin administration is less frequent (4–6%) (17) than
that observed with cisplatin or oxaliplatin (15–60%) (18), and is typically less severe. Risk of
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carboplatin peripheral neurotoxicity increased in patients older than 65 years and in patients
previously treated with cisplatin. Additionally, carboplatin does not cause the loss of hearing
that is seen in the majority of patients treated with cisplatin (19–21). Carboplatin-treated
patients also experience a lower incidence of nausea and/or vomiting and renal toxicity, when
compared to cisplatin based regimens (4,6).
Oxaliplatin frequently causes neutropenia, but is dose-limited in many cases by a purely
sensory neuropathy, which appears to be cumulative and, at least in a large part, reversible with
drug cessation. There are two patterns of neuropathy; an acute cold aggravated but transient
condition and a more chronic form which has onset after multiple exposures to the drug and
which often improves but does not disappear with drug cessation. Acute oxaliplatin
neurotoxicity can occur within hours of dosing as this may be precipitated or exacerbated by
exposure to cold temperature or cold objects and typically resolves within hours to days (22).
This acute neurotoxicity is dose-related and reversible. The more chronic pattern of sensory
neuropathy was observed in about 50% of study patients who received oxaliplatin with
infusional 5-FU/LV (23).
Platinum-induced peripheral neuropathy has elements common to all three agents with some
distinctive patterns. The neurologic complications of these three drugs occur in most cases, in
a cumulative manner. Cisplatin and carboplatin related neuropathies are often not completely
reversible and are seen as paresthesias in a stocking-glove distribution, areflexia, and loss of
proprioception and vibratory sensation. Loss of motor function has also been reported in
patients treated with cisplatin. After discontinuation of cis- or oxaliplatin therapy, the
neurotoxic symptoms may progress for up to 2 months. Patients may experience gradual
improvement, however more severe cases may have incomplete recovery (24). The incidence
of clinical neurotoxicity does not appear to be directly associated with anti-tumor response
(Fig. 2). Therefore, neurotoxicity is not merely a ‘necessary evil’, but can be approached as an
avoidable side effect of platinum agents.
Proposed platinum-drug mechanism of neurotoxicity
Cisplatin, carboplatin, and oxaliplatin differ in their solubility, chemical reactivity, oxygenated
leaving groups, pharmacokinetics, and toxicology (14). The leaving groups on each molecule
lead to differences in each platinum drug’s reactivity with nucleophiles, which is likely
contributing to the differences in toxicity (25). Platinum drugs undergo aquation, which is a
key step in the drug forming a complex with the target DNA (26). The result of this hydrolysis
is the formation of a positively charged molecule that then crosslinks to DNA, forming the
DNA/platinum adducts (26). The amount of DNA cross-links in DRG neurons at a given
cumulative dose was significantly correlated with the degree of neurotoxicity (27). Patient
trials of platinum agents have shown that the severity of neurotoxicity is commonly cisplatin
> oxaliplatin >> carboplatin. Based on the data from cisplatin, the differences in the degree of
neurotoxicity could be associated with their different plasma concentrations of the intermediary
products of the aquation to DNA adduct formation process (26). Cisplatin and oxaliplatin
undergo hydrolysis to a greater extent than carboplatin, which may contribute to the difference
in the associated neurotoxicity severity patterns.
Although the cellular damage is thought to be caused by the formation of these DNA adducts,
an additional complex composed of platinum-DNA-protein crosslinks (DPCLs) has been
proposed as a mechanism for the platinum antitumor activities, and studied specifically with
cisplatin (28). By covalently linking DNA with protein complexes, these DPCLs are able to
disrupt nuclear metabolism and spatial organization of chromatin, as well as inhibit DNA
replication and repair.
McWhinney et al. Page 3













The platinum drugs appear to effect the axons, myelin sheath, neuronal cell body and the glial
structures of the neurons (29). At the cellular level, the chemotherapy interferes with DNA
replication and metabolic function of the neurons (30). Platinum-based agents have the
propensity to enter the dorsal root ganglia and peripheral nerves (31) as opposed to the brain,
as these drugs have poor penetration through the blood-brain barrier (32). Levels of platinum
have been shown to be significantly higher in the dorsal root ganglia than in the brain and spinal
cord, which are protected by that barrier (32). It was previously thought that platinum drugs
entered the dorsal root ganglia through passive diffusion (20), although current data indicates
the presence of metal transporters that may be involved in their entrance into the cell (33).
Current research has shown insight into the mechanisms of nerve damage caused by the
platinum agents. After entering the DRG, the platinum agent forms an adduct with DNA.
Apoptosis has been observed in DRG neurons following cisplatin treatment both in vitro and
in vivo (34), and is correlated with increased platinum-DNA binding in these DRG neurons
(34). Oxaliplatin and cisplatin differ in their severity of neurotoxicity to the DRG. Cisplatin
produced about three times more platinum- DNA adducts in the DRG (35) than equimolar
doses of oxaliplatin, consistent with clinical observations that cisplatin is associated with
greater neurotoxicity.
Although the mechanism of the transition from a platinum-DNA adduct to neuronal apoptosis
is not fully understood, one proposal has suggested that the DNA repair machinery is unable
to repair the damaged DNA. Polymorphisms in the DNA repair genes, including genes in base
excision repair, nucleotide excision repair, mismatch repair, and double-strand break repair
pathways, cause the individuals to be less proficient in repairing carcinogen-induced damage
(36). It has also been proposed that the platinum-DNA adducts interfere with the normal
function of cellular proteins such as binding or interactions with other proteins (37).
Neurotoxicity in the peripheral nervous system is therefore a significant factor affecting the
efficacy of the platinum-based drugs, as patients may experience either more negative side-
effects than benefits from this drug class or be forced to forego further therapy with an active
agent. Recent studies have examined the effectiveness of a number of potential neuroprotectant
agents, such as erythropoietin (38), amofistine (39), carbemazepine (40), and supplements such
as Vitamin E or intravenous calcium or magnesium transfusions (29). The use of magnesium
and calcium supplementation with oxaliplatin appeared to reduce the anti-tumor effect in
advanced colorectal cancer in one study and is no longer a viable approach to avoid
neurotoxicity (41). Additionally, there has been a clinical trial using nimodipine, a calcium-
channel antagonist, in conjunction with cisplatin. This trial resulted in premature cessation of
treatment plus nimodipine due to significantly increased gastrointestinal toxicity. Acetyl-L-
carnitine is an additional intervention method used to treat chemotherapy-induced
neurotoxicity (42). Xaliproden is a non-peptidic neurotrophic drug that has recently been used
in oxaliplatin-treated patients experiencing neurotoxicity (43). A cytokine called LIF, or
leukemia inhibiting factor, was shown to have a role in diminishing peripheral neurotoxicity
in animal models, but was not confirmed in clinical samples. Because the platinum drugs target
the dorsal root ganglion and accumulate there, glutathione (GSH) had also been evaluated as
a neuroprotectant. Reduced GSH has a high affinity for heavy metals and could prevent the
platinum accumulation in the DRG (44,45). Org 2766 was shown to attenuate cisplatin-
associated neuropathy in ovarian cancer patients without adversely affecting the efficacy
(46). The efforts to establish a neuroprotective agent against cisplatin-induced neurotoxicity
have been to date unsuccessful, therefore future randomized controlled clinical trials must be
performed to continue this issue (47). For this reason, we must turn to genetics for efforts to
prevent this debilitating side-effect.
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In addition to efforts to identify a successful neuroprotective agent, there have been numerous
studies attempting to establish the role of various phenotypic markers for chemotherapy-
induced neurotoxicity. An accurate marker of neurotoxicity that would enable a quantitative
monitoring of progress of neurotoxicity or provide a prediction of the ultimate severity would
prove valuable in controlling this toxicity. Cavaletti et al. indicated a highly significant
correlation between the decrease in circulating levels of nerve growth factor (NGF) and the
severity of chemotherapy-induced neurotoxicity in patients treated with cisplatin and
paclitaxel, however it did not predict final neurological outcome (48). In addition, nerve
electrophysiological studies have been used to detect the progression of drug-induced
neuropathy (49). However, further studies to evaluate the effectiveness of both blood markers
and electrophysiology in detection of neurotoxicity progression must be performed to conclude
that these provide any sufficient benefit to the patient.
Many recent efforts have been made to determine genetic linkages as a cause of platinum-based
toxicity, in order to ultimately diminish these effects and augment the beneficial anti-tumor
qualities. The first and all-encompassing step of identifying genes that may play a role in the
variation of drug efficacy and individual response to the drug, a number of genome-wide studies
have been pursued. After discussing these broad studies, we review the specific targeted genetic
data and research efforts designed to circumvent this life-altering side-effect of platinum-based
cancer treatment.
Genome-wide studies to establish loci for chemotherapy response and
toxicity
Genome-wide studies are an effective tool to narrow the genome to a specific region that is
associated with drug response or other important phenotypes related to that drug. This allows
for the identification of putative candidate genes. Genome-wide expression analysis studies
have been used to correlate particular genomic signatures with drug response and development
of toxicity (50). Furthermore, genome-wide polymorphism studies describe variation between
individuals and associate these with response.
Platinum drug disposition
The disposition of a chemotherapeutic agents is often the key to determining the mechanism
by which they cause toxic effects in the human body. The disposition of a drug includes its
metabolism, absorption, distribution, and excretion. There are plausible connections between
genetic variability in candidate drug disposition genes variability in neurotoxicity rise (Table
1).
Glutathione S- Transferases (GST) are a family of enzymes that catalyze the conjugation of
glutathione to electrophilic toxins to inactivate them and aid in their excretion from the body.
The GST genes encode metabolizing enzymes that decrease the reactivity of toxins with
substrates in the body. They are divided into five classes. Genetic polymorphisms have been
found in a number of these, including GSTM1, GSTT1, GSTP1. Two independent studies in
advanced colorectal cancer patients treated with oxaliplatin looked at the GST genes for
variants patients that experienced grade 3 cumulative neuropathy. Ruzzo et al described 166
patients in which there was evidence of an association between the GSTP1 105 Val G/G allele
and the development of grade 3 neuropathy from oxaliplatin treatment (Table 1) (51).
Additionally, Lecomte and colleagues indicated that in a cohort of 64 patients, there was a
significant association between the GSTP1 105 Val G/G allele and risk of developing
neurotoxicity(52). A phase II study of 42 patients treated with irinotecan and carboplatin in
advanced non-small cell lung cancer also showed an association with this allele, where 5/9
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(26%) of those with the GSTP1 105 G/A or G/G genotypes had partial response when compared
to individuals with A/A who had no response (p = 0.057) (53).
Gamelin et al proposed that key components of the oxalate synthesis pathway could be
associated with platinum-drug neurotoxicity. In a study of an initial 10 patients followed by
an additional 135 patients treated with oxaliplatin, a minor haplotype in AGXT was able to
predict both acute and chronic neurotoxicity(54). Although this is the first study to indicate the
contribution of AGXT, it warrants further analysis in larger patient cohorts to determine the
predictive power of this haplotype.
Cell-entry mechanisms differ between drugs. As a heavy metal, platinum drugs must have a
particular method of entering their cell of interest. Metal transporters, such as the copper
transporters CTR1, ATP7A and ATP7B, have been of particular interest. Deletion of the
CTR1 gene in yeast leads to a significant accumulation of all three clinically available platinum
agents (55). Forced overexpression of human CTR1 in ovarian cancer cells increased cisplatin
uptake. CTR1 mediates cellular accumulation of platinum-containing drugs used in patients.
In order for neurotoxicity to develop, the drug must be capable of entering its target cells to
cause damage. Therefore any genes or proteins involved in the transport of platinum into or
out of cells could play a role in neurotoxicity development. However, there are no clinical
studies assessing the influence of genetic variation in platinum transporters on patient toxicity
or outcome.
Repair/ Resistance
DNA repair is an important mechanism for resistance to platinum-based therapy and possibly
the development of neurotoxicity. If the cell is able to repair the DNA that is attacked by the
platinum agent, then that agent will be unsuccessful in inducing apoptosis. Nucleotide excision
repair (NER) genes, such as excision repair cross-complementation group 1 (ERCC1) have
been hypothesized to play a role in the efficacy of platinum-based drugs. Among the numerous
studies performed assessing the association between NER genes and chemotherapy clinical
outcome, many have provided concrete evidence of an association (56). Park et al described
an association between the ERCC1 codon 118 polymorphism and clinical output in colorectal
cancer patients treated with platinum-based chemotherapy. This genotype could be a useful
predictor of clinical outcome not only for colorectal cancer patients, but also for patients with
epithelial ovarian cancer (57,58). To date, there have not been an association shown between
ERCC1 and chemotherapy neurotoxicity (51), however because the primary target of platinum
is DNA, the possibility remains. There are many genes whose effect on neurotoxicity have yet
to be studied. In a recent study in a population of ovarian cancer samples, there were a number
of genes examined that were treated with combination therapy, paclitaxel/carboplatin or
docetaxel/carboplatin, of which no associations with neurotoxicity were found (59).
Conclusions
There are many avenues that will need to be pursued to avoid or minimize neurotoxicity caused
by platinum drugs. Several are underway, such as studies to determine drug combinations to
prevent or minimize the toxicities. Unfortunately, these have resulted in only minor
contributions. An individual’s unique genetic code effects the disposition of each drug within
their body. To date, there have been many studies done examining DNA repair and drug
disposition genes in various patient populations treated with a number of different drugs,
including platinum-based drugs. Despite these efforts, specific targets have yet to be elucidated
that determine the precise association between platinum-agents and sensory neurotoxicity or
any of the other toxic side-effects that these drugs are associated with. By further and more
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detailed examination of the drug disposition as well as the specific phenotype it is causing,
researchers may identify concrete phenotype/genotype associations.
Data from clinical trials indicate a lack of correlation between the incidence of neurotoxicity
and tumor response rate. This supports the hypothesis that by eliminating or decreasing
neurotoxicity, the effectiveness of the drug will not be diminished. However, it will take a more
concerted effort to discover meaningful predictors of this serious adverse drug effect. Until the
concrete phenotype/genotype associations have been established to enable individualized
therapy, a physician should be aware of the risk of the severe, life-altering side-effect of
neurotoxicity. When the symptoms become extreme, it may be advisable to cease therapy or
to offer an alternative treatment in order to salvage the patient’s quality of life.
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Percentage of neurotoxicity vs. response rate (RR) for each platinum drug treatment from
platinum-containing trials (4,11,51,62–74).
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Table 1
Pharmacogenetic Associations with Platinum Treatment (51,52,60,61)

















Selected SNPs in each gene show no
significant association
Marsh, et al (60)
Advanced Colorectal GSTP1 166 FOLFOX I105V homozygous Ile alleles show
increase in neurotoxicity (p<0.01)
Ruzzo, et al (51)
Colorectal SCN1A 152 5-FU/Oxaliplatin T1067A T/T genotype have decreased
neurotoxicity (p=0.002)
Nagashima, et al (61)
GI Cancer GSTP1 64 Oxaliplatin I105V homozygous Ile allele shows
increased frequency of grade 3
neurotoxicity (p=0.002)
Lecomte, et al (52)
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